Questions About Gantenerumab Failure Remain, But Roche Is Not Yet Finished With Alzheimer’s
Full Data Presented At CTAD Congress
Executive Summary
Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.